Latest stories on BIO
Bio-Rad: Favorable Read-Across From Investor Event
Seeking Alpha63 · neutralanalyst
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Barron's52 · neutralgeneral
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.
Barron's28 · bearishanalyst
S&P 500 Futures Decline in Premarket Trading; Bio-Rad Labs A, Fabrinet Lag
Barron's42 · neutralgeneral
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
Yahoo Top48 · neutralgeneral
Changes to full-year guidance for BioMar
GlobeNewswire34 · bearishearnings
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript
Yahoo Top67 · bullishearnings
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript
The Motley Fool68 · bullishearnings
Bio-Rad price target raised to $390 from $370 at RBC Capital
The Fly63 · neutralanalyst
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary
Yahoo Top50 · neutralearnings
Bio-Rad forecasts 2026 currency-neutral revenue growth of (-3%) to +0.5% while targeting $30M-$35M net cost savings by end of 2027
Seeking Alpha38 · neutralearnings
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Bio-Rad Restructuring Plan Announced to Boost Competitiveness
TipRanks56 · neutralgeneral
Bio-Rad Laboratories, Inc. Non-GAAP EPS of $2.62 beats by $0.87, revenue of $651M beats by $27.01M
Seeking Alpha68 · bullishearnings
BIO-RAD LABORATORIES, INC. (BIO-B) files 8-K
SEC 8-K50 · neutralgeneral
Bio-Rad Reports Second-Quarter 2026 Financial Results
StockTitan57 · neutralearnings
Madison Mid Cap Fund Q2 2026 Portfolio Activity
Seeking Alpha56 · neutralgeneral
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
StockTitan50 · neutralearnings
Parnassus Value Equity Fund Q2 2026 Portfolio Review
Seeking Alpha38 · neutralgeneral
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential
Seeking Alpha63 · neutralgeneral
Merck KGaA to acquire Bio-Techne in $11.3 billion deal
Yahoo Finance67 · bullishm&a
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
The Motley Fool57 · neutralanalyst
Activist Investor Ananym Urges Bio-Techne to Consider Selling
Bloomberg48 · neutralgeneral
Bio-Rad Laboratories, Inc. (BIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral